(OTCBB:RGBP) Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell For Solid Tumors

Feb. 03, 2016 10:52 AM ETRGBP
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2014

Robert E. Kreh - Principal - Small Cap Solutions, LLC

Business Development-Marketing Consultation-IR

Over 30 years Of Management-Sales-Corporate Finance & IR

Connection for Sources of Pubco & Private Company

Funding Financing & Debt Restructure

www.smallcapsolutions.com

www.regenbiopharmainc.com (OTCPK:RGBP)

Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors

Company Augments Potency of its Existing NR2F6 Silenced CAR-T Approach By Leveraging Innate Immune Activation Molecules

The filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.

Remarkable clinical results have been obtained by numerous investigators utilizing CAR T cells in the treatment of leukemia and lymphomas

http://finance.yahoo.com/news/regen-biopharma-inc-files-patent-133000462.html

Recent News Items of Interest:

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

http://finance.yahoo.com/news/regen-biopharma-submits-application-fda-133000880.html

Regen BioPharma, Inc. and the National Institutes of Health to Collaborate

http://finance.yahoo.com/news/regen-biopharma-inc-national-institutes-133000075.html

Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXelleratehttp://finance.yahoo.com/news/regen-biopharma-inc-receives-fda-133000659.html

We believe Regen is a Long Play with imminent Short Term Gain potential.

They are a "Cutting Edge" Bio Tech - Stem Cell R&D Company that offers exponential growth.

Regen in our opinion will one day be either the Leader in many areas of Stem Cell treatment and/or could be a very attractive Candidate for a Buy Out or Merger.

Areas of Focus are:

Various Cancers and the treatment of - Breast, Liver, Kidney, Prostate

(dCellVax is on the verge of & awaits FDA clearance for Phase I Human/Patient clinical trials for Breast Cancer)

Treatment of Rare Blood Disorders & Diseases (HemaXellerate FDA "Cleared/Approved " for Human/Patient clinical trials (aPlastic Anemia) Phase I to commence soon.

Treatment of Leukemia

We can Assist any Publicly Traded Company Gain Greater Exposure Creating Increased Awareness and Liquidity in the Market Place (Retail or Private)

** Contact us for Custom Tailored Plans for Your situation

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.